> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Oncolytics Biotech Fast Track for Reolysin
- URL: https://www.fdaweb.com/oncolytics-biotech-fast-track-for-reolysin/
- Published: 2017-05-08T12:00:00.000Z
- Updated: 2026-09-14T22:22:14.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5138638

FDA has granted Oncolytics Biotech a fast track designation for Reolysin, an immuno-oncology viral agent for treating metastatic breast cancer. Last month, the company reported Phase 2 data from an open-label, randomized study assessing the therapeutic combination of intravenously-administered Reolysin given in combination with paclitaxel versus paclitaxel alone in patients with advanced or metastatic breast cancer. “The combined treatment demonstrated a statistically significant increase in median overall survival,” the company says. Oncolytics adds that it will soon request an End-of-Phase 2 meeting with the agency to obtain scientific guidance for a Phase 3 program.